Neurophysiologic approach to pruritus and pain in cancer patients

Journal of B.U.ON.

Volumn 11, Issue 2, 2006, Pages 143-152

  Igic, Rajko ^a,b   Alexander, B ^a  

^a Jr Hospital of Cook County   (United States)

^b Anesthesiology Research Laboratory   (United States)

Author keywords

Cancer; Neurophysiology of itch; Neurophysiology of pain; Pain; Pruritus

Indexed keywords

ALKALOID; ALKALOID DERIVATIVE; ALKYLATING AGENT; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BRADYKININ; CALCITONIN GENE RELATED PEPTIDE; CONTRAST MEDIUM; CYCLOSPORIN; DERMATOLOGICAL AGENT; ENDOTHELIN; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; LIDOCAINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROKININ A; OPIATE DERIVATIVE; PROSTAGLANDIN; SEROTONIN; SUBSTANCE P; THALIDOMIDE; VANILLOID RECEPTOR;

CANCER PAIN; CANCER PATIENT; CLINICAL ASSESSMENT; ENZYME INHIBITION; HUMAN; MOLECULAR MECHANICS; NEUROPATHIC PAIN; NEUROPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRURITUS; QUALITY OF LIFE; REVIEW;

HUMANS; NEOPLASMS; NERVOUS SYSTEM PHYSIOLOGY; PAIN; PRURITUS; QUALITY OF LIFE;

EID: 33751085865     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Cleeland CS, Gonin R Hatfield AK et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592-596.
2. Coyle N, Adelhardt J, Foley KM, Portenoy RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 1990;5:83-93.
3. Grond S, Zech D, Difenbach C, Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 1994;9:372-382.
4. Beers MH, Berkow R. The Merck manual of diagnosis and therapy. Whitehouse Station, Merck, 1999.
5. Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003;361:690-694.
6. Cassileth BR, Lusk EJ, Guerry DP et al. "Catalyst" symptoms in malignant melanoma. J Gen Intern Med 1987; 2:1-4.
7. Braverman IM. Skin manifestations of internal malignancy Clin Geriatr Med 2002;18:1-19.
8. Ballantyne JC, Loach AB, Carr DB. Itching after spinal and epidural opiates. Pain 1988;33:149-160.
9. Schug SA, Zech D, Doff U. Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 1990;5:27-32.
10. Igic R, Rabito SF, Glusman S. Cancer pain management. Additional therapeutic modalities. Arch Oncol 1995;3:107.
11. Bosonnet L. Pruritus: scratching the surface. Eur J Cancer Care 2003;12:162-165.
12. Levy MH. Integration of pain management into comprehensive cancer care. Cancer 1989;63 (11 Suppl): 12328-12335.
13. Jacox A, Carr DB, Payne R et al. The management of pain: clinical practice guideline. No. 9. Rockville, MD: Agency for Health Care Policy and Research, 1994 (AHCPR publication No. 94-0592.)
14. Doyle D, Hanks GWC, McDonald N (eds). Oxford textbook of palliative medicine (2nd edn). New York: Oxford University Press, 1998.
15. Carr D, Goudas L, Lawrence D et al. Management of cancer symptoms: Pain, depression, and fatigue. Evidence report/technology assessment No.61. Rokville, Md: Agency for healthcare research and quality, 2002.
16. Carver AC, Foley KM (eds). Management of cancer pain. Hamilton and London: Decker, 2003.
17. Wall and Melzack's textbook of pain. Elsevier/Churchill Livingstone, 2005.
18. Tuckett RP. Itch provoked by electrical stimulation of the skin. J Invest Dermatol 1982; 79: 368-373.
19. Same M, Hanna D, Lotti T. Itch, pain, and metaesthetic sensation. Dermatol Ther 2005;18:308-313.
20. Schmeltz M, Schmidt R, Bickel A et al. Specific C-receptors for itch in human skin. J Neurosci 1997;8003-8008.
21. Standler S, Moormann C, Schumacher M et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol 2004; 13: 129-139.
22. Dukes MNG (ed). Meyler's side effects of drugs. Amsterdam: Elsevier, 1988.
23. Waxler B, Dadabhoy ZP, Stojiljkovic L, Rabito SF. Primer of postoperative pruritus for anesthesiologists. Anesthesiology 2005; 103; 168-178.
24. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24:253-262.
25. Hagermark O, Stranberg K, Gronneberg R. Effects of histamine receptor antagonists on histamine-induced responses in human skin. Acta Derm Venereol 1972; 59: 297-300.
26. Fjellner B, Hagemark O. Experimental pruritus evoked by platelet activating factor (PAF-acether) in human skin. Acta Derm Venereol 1985; 65: 409-412.
27. Wallengren J. Neuroanatomy and neurophysiology of itch. Dermatol Ther 2005; 18: 292-303.
28. Gaspari AA, Lotze MT, Rosenberg SA et al. Dermatologic changes associated with interleukin 2 administration. JAMA 1987; 258: 1624-1629.
29. Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporine A in atopic dermatitis. Acta Derm Venereol 1990; 70: 323-329.
30. Richardson JD, Vasko MR. Cellular mechanisms of neurogenic inflammation. J Pharm Exp Ther 2002; 302: 839-845.
31. Park KA, Vasko MR. Lipid mediators of sensitivity in sensory neurons. Trends Pharmacol Sci 2005; 26: 571-577.
32. Massey EW: Unilateral neurogenic pruritus following stroke. Stroke 1984; 15: 901-903.
33. Nagasako EM, Oaklander A, Dworkin RH. Congenital insensitivity to pain: an update. Pain 2003; 101: 213-219.
34. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999; 57:1-164.
35. Miller BA, Woolf CJ. Nociceptive sensitization: the peripheral and central mechanisms responsible for the generation of clinical pain. In: G. Adelman, BH Smith (eds): Encyclopedia of Neuroscience (Vol. II). Amsterdam: Elsevier, 1999, pp 1479-1483.
36. Price DD. Central neural mechanisms that interrelate sensory and affective dimensions of pain. Mol Interv 2002; 2: 392-402.
37. Treede RD, Kenshalo DR, Gracely RH et al. The cortical representation of pain. Pain 1999; 79: 105-111.
38. Berthier M, Starkstein S, Leiguarda R. Asymbolia for pain: a sensory-limbic disconnection syndrome. Ann Neurol 1988; 24: 41-49.
39. Schmelz M. Itch and pain. Dermatol Ther 2005; 18: 304-307.
40. Schmelz M. Itch -mediators and mechanisms. J Dermatol Sci 2002; 28: 91-96.
41. Urashima R, Mihara M. Cutaneous nerves in atopic dermatitis - a histological, immunohistochemical and electron microscopic study. Virchows Arch 1998; 432: 363-370.
42. Ikoma A, Fartasch M, Heyer G et al. Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch. Neurology 2004; 62: 212-217.
43. Scheinfeld N. The role of gabapentin in treating diseases with cutaneous manifestations and pain. Int J Dermatol 2003; 42: 491-495.
44. Peharda V, Gruber F, Kastelan M et al. Pruritus: an important symptom of internal diseases. Acta Dermatoven Alpina Pann Adriat 2000; 9: 92-104.
45. Cohen PR. Skin clues to primary and metastatic malignancy. Am Fam Physician 1995; 51: 1199-1204.
46. Mahajan R, Grover VK. Neuraxial opioids and Koebner phenomenon: implications for anesthesiologists. Anesthesiology 2003; 99: 229-230.
47. Rubin AI, Stiler MJ. A listing of skin conditions exhibiting the Koebner and pseudo-Koebner phenomena with eliciting stimuli. J Cutan Med Surg 2002; 6: 29-34.
48. Chopra KF, Cohen PR. Linear basal cell carcinomas: report of multiple segmental tumors localized to a radiotherapy port and review of the literature. Tex Med 1997; 93: 57-59.
49. Roosen T. Cutaneous metastases. Med Clin North Am 1980; 64: 885-900.
50. Brownstein MH, Helwig EB. Spread tumors to the skin. Arch Dermatol 1973; 107: 80-86.
51. Andreev VC, Petkov I. Skin manifestation associated with tumor of the brain. Br J Dermatol 1975; 92: 675-678.
52. Bergasa NV. The pruritus of cholestasis. Semin Dermatol 1995; 14: 302-312.
53. Mela M, Mancuso A, Burroughs AK. Review article: pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther 2003; 17: 857-870.
54. Schlappack O. Homeopathic treatment of radiation-induced itching in breast cancer patients. A prospective observational study. Homeopathy 2004; 93: 210-215.
55. Thomas DA, Giles FJ, Albitar M et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 2006; (Epub ahead of print).
56. Portenov RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273-281.
57. Byrne TN. Spinal cord compression from epidural metastases. N Engl J Med 1992; 327: 614-619.
58. Ripamonti C, Longo M. Cancer pain syndromes and pharmacotherapy of cancer pain. Arch Oncol 2004; 12: 168-170.
59. Levy MH. Integration of pain management into comprehensive cancer care. Cancer 1989; 63:2328-2335.
60. Serrlin RC, Mendoza TR, Nakamura Y et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995; 61: 277-284.
61. Clarck WC, Yang JC, Tsui SL et al. Unidimensional pain rating scales: a multidimensional affect and pain (MAPS) analysis of what they really measure. Pain 2002; 98: 241-247.